Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a left ventricular ejection fraction (LVEF) of 50% or greater.
You have advanced/ metastatic solid tumors that have relapsed or progressed on or after standard systemic treatments or for which no standard treatment is available.
You have measurable disease as assessed by the investigator according to RECIST version 1.1 criteria.
Has an ECOG PS of 0-1.
You have adequate organ functions within 7 days prior to Day 1 of Cycle 1.
You have received a full course of treatment and have had a complete treatment washout period prior to Day 1 of Cycle 1.
You are willing to undergo pre-existing resected tumor samples or fresh tumor biopsy for the measurement of Trop-2 level and other biomarkers if no contraindication.
You are capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.